home / stock / vyne / vyne news

VYNE News and Press, VYNE Therapeutics Inc Com From 11/18/22

Stock Information
Company Name: VYNE Therapeutics Inc Com
Stock Symbol: VYNE
Market: NASDAQ
Website: vynetherapeutics.com
Menu
VYNE VYNE Quote VYNE Short VYNE News VYNE Articles VYNE Message Board
Get VYNE Alerts

News, Short Squeeze, Breakout and More Instantly...
VYNE - VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...
VYNE - VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...

VYNE - VYNE Therapeutics GAAP EPS of -$0.16, revenue of $0.2M

VYNE Therapeutics press release ( NASDAQ: VYNE ): Q3 GAAP EPS of -$0.16. Revenue of $0.2M (+53.8% Y/Y). As of September 30, 2022, VYNE had cash and cash equivalents and restricted cash of $35.6 million. For further details see: VYNE Therapeutics GAA...

VYNE - VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and development of oral, BD2 selective VYN202 program Expanded analysis of FMX114 Phase 2a tria...
VYNE - VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions...

VYNE - VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics press release ( NASDAQ: VYNE ): Q2 Non-GAAP EPS of -$0.13 beats by $0.02 . Revenue of $0.13M (-55.2% Y/Y) beats by $0.03M . As of June 30, 2022, VYNE had cash and cash equivalents of $42.8 million. Shares -4% PM. For fu...

VYNE - VYNE Therapeutics Reports Second Quarter 2022 Financial Results

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...
VYNE - Vyne sheds 31% as mid-stage trial for atopic dermatitis candidate fails

The shares of nano-cap pharma VYNE Therapeutics ( NASDAQ: VYNE ) fell ~31% in the pre-market Wednesday after the company announced that its atopic dermatitis candidate FMX114 failed to reach the main goal in a mid-stage study. The Phase 2a segment of a Phase 1b/2a clinic...

VYNE - VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...

VYNE - VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...
Previous 10 Next 10